Concern over the potential negative impact to food and beverage sales from obesity medications such as Ozempic and Wegovy is overblown.

This summer, Morgan Stanley rightfully dug into whether the rapidly growing use of diabetes drugs for weight loss would dampen food and beverage sales in a country racked with obesity. Analysts at the firm estimate a -2.0% to -3.0% decline in carbonated soft drink and snack consumption in 2035 driven by the drugs. Other firms...